Recent data have suggested that the iodothyronine, 3,5-diiodo-l-thyronine (T 2 ), has selective thyromimetic activity. In vivo, T 2 has been shown to suppress TSH levels at doses that do not produce significant peripheral manifestations of thyroid hormone activity. Furthermore, T 2 has been shown to produce smaller increments in peripheral indices of thyroid status than does T 3 , when doses resulting in equivalent suppression of circulating TSH are compared. We have assessed the selective thyromimetic activity of T 2 in vivo and in vitro, and performed in vitro studies to assess the potential molecular basis for these selective properties. T 2 was 100-fold less potent than T 3 in stimulating GH mRNA levels in GH 3 cells. In contrast, the iodothyronines were almost equivalent in their ability to downregulate TR 2 mRNA levels in this cell line. Both 3,3 -diiodo--thyronine and thyronine exhibited no significant thyromimetic effects on either process. In vivo, doses of T 2 and T 3 that were equivalent in their induction of hepatic malic enzyme (ME) mRNA did not produce equivalent suppression of circulating TSH, with T 2 being only 27% as effective as T 3 . T 2 was up to 500-fold less potent than T 3 in displacing [
INTRODUCTION
The major iodothyronine secreted by the thyroid gland, thyroxine (T 4 ), is metabolized through outer ring deiodination to the thyroid hormone 3,5,3 -triiodo-l-thyronine (T 3 ), which has diverse effects on growth, development and metabolism. These effects are mediated through three specific nuclear receptors: TR 1, TR 1 and TR 2. These TRs differ in their pattern of expression and in their regulation by a number of factors, including T 3 itself (Lazar 1993) . The conserved diversity, variation in expression and differential regulation of the TRs raise the possibility of isoform-specific functions. There are data supporting such specificity. TR 1 preferentially modulates the activities of the thyrotropin-releasing hormone (TRH) and myelin basic protein gene promoters (Farsetti et al. 1992 , Lezoualc'h et al. 1992 . Furthermore, TR 2 has been implicated as the major TR mediating the effects of T 3 on the growth hormone (GH) gene. Treatment of GH 3 cells with sodium butyrate and TRH specifically decreases TR 2 levels, with a coincident decrease in T 3 -stimulated GH gene expression (Lazar 1990 , Jones & Chin 1992 . However, these data reflect properties of overexpressed TRs on heterologous promoters or, in the case of sodium butyrate and TRH, the indirect manipulation of TRs, with potential confounding parallel effects. Understanding of the molecular basis of the diversity and specificity of T 3 action would be greatly enhanced by the development of iodothyronine analogs with differential interactions with TRs and selective thyromimetic effects.
Further outer ring deiodination of T 3 yields 3,5-diiodo--thyronine (T 2 ), generally considered to be inactive. However, it has recently been shown that T 2 is able to suppress thyroid-stimulating hormone (TSH) levels in vivo, at doses that do not produce significant peripheral manifestations of thyroid hormone activity (Horst et al. 1995) . Furthermore, when doses producing equivalent suppression of TSH were compared following long-term administration, T 2 produced significantly smaller changes in peripheral indices of thyroid hormone activity than did T 3 . In addition to indicating that T 2 has significant thyromimetic activity, these data raise the interesting possibility that the compound may be a selective agonist, with preferential activity on certain targets. In this study, we have examined the ability of T 2 to regulate T 3 responsive genes in vivo and in vitro. We present evidence that T 2 has selective thyromimetic activity, and describe data on the molecular basis of this selectivity.
MATERIALS AND METHODS

Cell culture
GH 3 cells were grown to 70% confluence in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. For experiments in which the effect of iodothyronines on T 3 -dependent gene expression was assessed, cells were transferred to media supplemented with 10% hormone-stripped fetal bovine sera for 48 h before experimentation, media being changed daily. T 3 (Sigma) and T 2 (custom synthesized by Henning, Berlin, Germany) were added to parallel cultures to achieve final concentrations ranging from 0·1 n to 10 µ. Incubations were for 24 h. Vehicle was added to appropriate control incubations. To test the specificity of the T 2 response further, 3,3 -diido--thyronine (sT 2 ) or thyronine (T0; Henning) was added to additional parallel incubations. The method used to synthesize T 2 precluded contamination with T 3 or T 4 . Formal assessment by HPLC detected no other contaminating iodothyronines (sensitivity >99·99%, C Horst and H Rokos, personal communication).
In vivo effects of T 2 on malic enzyme (ME) gene expression and TSH secretion
The thyromimetic activity of T 2 was tested in male Wistar rats, rendered hypothyroid by 3 weeks of treatment with propylthiouracil (0·05% wt/vol in drinking water). Animals were maintained on propylthiouracil and treated with T 2 (100 µg/100 g body weight), T 3 (1 µg/100 g body weight), or placebo by i.p. injection, daily for 7 days. Animals were killed by decapitation. Liver was dissected and snap frozen for subsequent preparation of RNA. Plasma TSH was measured by specific RIA (Prof. C Emerson, University of Massachusetts Medical Center, USA). Statistical analysis was performed by Student's t-test.
RNA extraction and Northern blot analysis of TR 2, GH and ME mRNAs GH 3 cells were harvested in 4  guanidinium thiocyanate, 0·5% sodium n-lauryl sarcosine, 25 m sodium citrate and 0·1  mercaptoethanol. RNA was prepared by centrifugation through 5·7  cesium chloride. The pellet was washed twice with 0·3  sodium acetate, ethanol-precipitated on each occasion and finally resuspended in RNAse-free distilled water. Liver RNA was prepared by a single-step method. Briefly, fragments of snap frozen rat liver were homogenized on ice in 6 ml 4  guanidinium thiocyanate, 0·5% sodium n-lauryl sarcosine, 25 m sodium citrate and 0·1  mercaptoethanol. To this homogenate were added 600 µl 2  sodium acetate and 6 ml water-saturated acidic phenol (pH 7·4), followed by 1·2 ml chloroform. The suspension was incubated on ice for 15 min and the aqueous and organic phases separated by centrifugation at 4 C. The aqueous phase was decanted, re-extracted with an equal volume of chloroform and the RNA precipitated with an equal volume of ice-cold isopropanol. After centrifugation, the RNA pellet was washed once in 70% ethanol, dried under vacuum and resuspended in 200 µl RNAse-free distilled water. The purity and concentration of RNA was assessed by optical density (OD 260 /OD 280 ) and the integrity of 18S and 28S ribosomal RNA after electrophoresis.
Either 5 µg GH 3 cell RNA or 20 µg rat liver RNA were subjected to electrophoresis through 1% agarose containing 1·8% (vol/vol) formaldehyde. Running buffer was 1 MOPS. After electrophoresis, RNA was transferred to Duralon membranes (Dupont, Boston, MA, USA). Hybridization with riboprobes was in 50% formamide, 5 SSC, 5 Denhardt's solution (2% wt/vol polyvinyl pyridoline, 2% wt/vol BSA, 2% wt/vol Ficoll 400), 5% SDS, 500 µg/ml yeast RNA at 65 C. Membranes were washed in 0·2 SSC, 0·1% SDS, twice at room temperature and twice at 65 C. For incubations with cDNA probes, membranes were pre-hybridized in 50% formamide, 5 SSC, 10 Denhardt's solution, 50 m sodium phosphate (pH 6·7), 1% SDS, 1 µg/ml salmon sperm DNA (Sigma, St Louis, MO, USA). Subsequent hybridization was in 50% formamide, 5 SSC, 5% dextran sulphate, 20 m sodium phosphate (pH 6·7), 1 Denhardt's solution, 0·5% SDS, 20 µg/ml salmon sperm DNA at 45 C. Membranes were washed successively at room temperature in 1% SDS/1 SSC, 0·5% SDS/0·5 SSC, 0·1% SDS/ 0·1 SSC twice, and finally at 50 C in 0·1% SDS/0·1 SSC.
[ 32 P]-Labeled riboprobes for rat GH and rat TR 2 were prepared by standard procedures from the respective cDNAs subcloned in pBS-KS (Page et al. 1981 , Hodin et al. 1989 . A [ 32 P]cDNA rat ME probe was synthesized by the random primer method from a 1 kb partial cDNA in pUC 13-JM103 (Dozin et al. 1986) . A [ 32 P]-labeled cDNA cyclophilin probe was made by the random primer method, using a 900 bp cyclophilin sequence in pBS (Danielson et al. 1988) .
GH, TR 2 and ME mRNA expression were quantified by a phosphoimager (Molecular Dynamics), and corrected for loading and transfer by normalizing to a non-regulated cyclophilin mRNA signal.
Binding of T 2 by in vitro translated TRs and GH 3 cell nuclear extracts
The relative affinities of TRs for T 2 and T 3 were determined by a competitive binding assay using in vitro translated TRs, and GH 3 cell nuclear extracts. Rat TR 1, TR 2 and human TR 1 were prepared by in vitro translation (TNT Reticulocyte Lysate System, Promega, Madison, WI, USA) from their respective cDNAs; pBS-KS-rTR 1 (Lazar et al. 1988) , pcDNA1/Amp-hTR 1, the human TR 1 cDNA sub-cloned to the EcoR1 site of pcDNA1/Amp (Hodin et al. 1989) , and pBS-rTR 2 (Hodin et al. 1989) .
Binding studies were performed as previously described (Suen & Chin 1993) . Briefly, 2-5 µl of in vitro translated TR or 40 µg of nuclear extract were incubated for 18 h at 4 C with 2 n [
125 I]-T 3 (2200 Ci/mmol; Dupont, NEN Research Products) and increasing amounts of either non-labeled T 2 or T 3 in a total reaction volume of 150 µl KMTD (0·3  KCl, 1 m MgCl 2, 10 m Tris-HCl (pH 8·0), 1 m dithiothreitol (DTT)). Dowex AG-1 8 was used to separate bound and free ligand.
Preparation of GH 3 cell nuclear extracts
GH 3 cell nuclear extracts were prepared as previously described (Sugawara et al. 1993) . Briefly, cells were lysed in 3 volumes of buffer containing 20 m Hepes (pH 7·8), 1·5 m MgCl 2 , 40 m KCl, 0·5 m DTT and 0·1 m phenylmethylsulphonyl fluoride (PMSF). Nonidet P-40 10% (vol/vol) was added to a final concentration of 0·5%. The suspension was incubated on ice for 10 min. Nuclei were then isolated by centrifugation (15 000 g for 30 s at 4 C). The nuclear pellet was resuspended in an equal volume of buffer containing 20 m Hepes (pH 7·8), 0·6  KCl, 0·02 m ZnCl 2 , 0·2 m EDTA, 0·5 m DTT, 0·1 m PMSF and 1 µg/µl pepstatin, and incubated on ice for 30 min. After further centrifugation (15 000 g for 20 min at 4 C), the resultant supernatant was dialyzed for 4 h against buffer containing 20 m Hepes (pH 7·8), 5 m mercaptoethanol, 10% (vol/vol) glycerol, 50 m NaCl, 2 m EDTA and 0·1 m PMSF. Protein concentration was determined by standard methods. Aliquots were rapidly frozen and stored at 80 C. Nuclear extracts were used within 2 weeks of preparation.
Electrophoretic mobility shift assay (EMSA) to determine effect of T 2 binding on TR conformation
Inverted palindrome T 3 response element (F2-TRE) DNA fragments were end-labeled with T 4 polynucleotide kinase in the presence of [ -32 P] ATP. Gel-purified probes were incubated with 2·5 µl in vitro translated TR 1 at room temperature for 30 min in the presence of 100 m Tris-HCl (pH 7·5), 50 m NaCl, 5% (vol/vol) glycerol, 1 m EDTA, 1 m DTT and increasing amounts of either T 2 or T 3 to final concentrations of up to 10 µ; total reaction volume 20 µl. Unprogrammed reticulocyte lysate was added to appropriate control incubations. Reaction mixtures were subjected to electrophoresis through a 5% polyacrylamide gel (29:1 acrylamide-bisacrylamide) in 0·5 Trisborate-EDTA buffer for 90 min at 4 C. Gels were dried and subjected to autoradiography. TR 1 homodimer formation in individual reactions was quantified using a phosphoimager.
RESULTS
Effect of T 2 on pituitary gene expression in vitro: differential thyromimetic regulation of GH and TR 2 mRNAs in GH 3 cells
The effects of T 2 on GH and TR 2 gene expression, relative to those of T 3 , were tested in vitro by Northern blot analysis. Maximum stimulation of GH mRNA and downregulation of TR 2 mRNA were similar for both iodothyronines (Figs 1 and 2 ). However, T 2 was approximately 100-fold less potent in the stimulation of GH gene expression than T 3 , as reflected in doses producing both maximal and half-maximal responses. Maximal stimulation of GH gene expression was produced by 1·00 µ T 2 and half-maximal by 40 n T 2 , compared with maximal and half-maximal responses to T 3 at 0·01 µ and 0·4 n respectively. In contrast, T 2 was only 0·5-fold less potent than T 3 in decreasing TR 2 gene expression. Maximal downregulation of TR 2 mRNA was achieved at 0·1 µ T 2 and 0·05 µ T 3 ; indeed, halfmaximal reductions in TR 2 expression occurred at equivalent doses of the iodothyronines (Table 1) . In parallel experiments, neither sT 2 nor T0 (0·1 n-10 µ) produced significant stimulation of GH mRNA, or downregulation of TR 2 mRNA in GH3 cells in culture (data not shown). This is in accordance with the known thyromimetic activity of these analogs (Koerner et al. 1975 , Jorgensen 1978 .
These data indicate that T 2 has specific differential thyromimetic effects on pituitary gene expression in vitro.
The effect of T 2 on ME gene expression and plasma TSH levels: differential thyromimetic effects in vivo
To assess the relative efficacy of T 2 and T 3 in vivo, we studied their effects on the induction of liver ME mRNA and reduction of plasma TSH. Reduction in TSH by 1 µg/100 g body weight T 3 was much greater than that by 100 µg/100 g body weight T 2 (7·4-fold compared with 2·0-fold; P<0·01; Fig. 3 ). In contrast, induction of ME mRNA was equivalent in T 3 -and T 2 -treated groups (11·6-fold compared with 9·5-fold; P>0·05, NS; Fig. 4 ). These data indicate that T 2 is more effective in the induction of hepatic ME gene expression than in suppression of plasma  1. Dose-response curves of GH mRNA to T 2 and T 3 in vitro. GH 3 cells were incubated with T 2 or T 3 in vitro as described in Methods. GH mRNA was assessed by Northern blot analysis and data expressed as arbitrary phosphoimager units (PIU), relative to a non-regulated cyclophilin RNA. TSH. Treatment with T 2 at a dose sufficient to produce induction of ME mRNA equivalent to that produced by 1 µg/100 g body weight T 3 resulted in significantly less suppression of plasma TSH than that produced by 1 µg/100 g body weight T 3 .
The binding of T 2 to TRs in vitro
To determine if the basis for these differential effects of T 2 was related to differences in the binding of the iodothyronine by specific TR isoforms, we assessed the relative affinity of  2. Dose-response curves of TR 2 mRNA to T 2 and T 3 in vitro. GH 3 cells were incubated with T 2 or T 3 in vitro as described in Methods. TR 2 mRNA was determined by Northern blot analysis and data expressed as PIU, relative to a non-regulated cyclophilin RNA. Table 2 . On the basis of these displacement data, the affinities of in vitro translated TR 1, TR 1 and TR 2 for T 3 are 40-500-fold those for T 2 . The ED 50 of T 2 binding to in vitro translated TR 2 is lower than that of the other TRs, suggesting that the binding of T 2 to TR 2 is of a higher affinity than that of the other isoforms. Apparent affinities of in vitro translated TRs for T 3 are in keeping with previous data (Schueler et al. 1990) . Similar data were obtained using GH 3 cell nuclear extracts as a source of TRs, excluding pituitary specific cofactors as a requirement for differential T 2 -TR interaction. These data indicate that the basis for the differential thyromimetic effects of T 2 is not related to differences in the binding of the iodothyronine by specific TR isoforms.
The effect of T 2 on TR homodimer formation
In the absence of T 3 , TRs can bind to F2-TREs as homodimers. The binding of T 3 by this TR-DNA complex produces a conformational change in the TR which results in dissociation of the homodimer from the TRE (Yen & Chin 1994) . To determine whether the relative affinity of TRs for T 2 in a competitive binding assay directly parallels the functional ability of T 2 to produce changes in TR conformation, we studied the properties of T 2 relative to those of T 3 in the dissociation of TR 1 homodimers from an F2-TRE by EMSA (Fig. 6 ). In keeping with previous data, T 3 produced a significant decrease in TR 1 homodimer-TRE complex formation at concentrations of 0·01 n, with half-maximal responses at 5 n (Yen et al. 1992) . Though maximum effects were similar, T 2 did not produce an effect on homodimer formation at concentrations less than 1 n, half-maximal effect being obtained at 1·5 µ. Functional assessment of iodothyronine interactions by EMSA are thus consistent with in vitro binding data, indicating that T 3 is approximately 1000-fold more potent than T 2 in dissociating TR 1 homodimers from DNA. These data confirm that the relative ability of T 2 to produce conformational change in TR 1 is in keeping with the affinity of the TR for the iodothyronine.
DISCUSSION
Of the iodothyronines generated through deiodination of T 4 , only T 3 is considered biologically active (Jorgensen 1978) . T 2 has less than 1% of the  3. Plasma TSH response to T 2 and T 3 in vivo. Plasma TSH response to 7 days treatment with vehicle alone (control), T 2 (100 µg/100 g body weight) or T 3 (1 µg/100 g body weight) in hypothyroid rats as determined by specific RIA. Data points are means ..; n=5.
 4. Hepatic ME mRNA response to T 2 and T 3 in vivo. Hepatic ME mRNA response in hypothyroid rats to 7 days treatment with vehicle alone (control), T 2 (100 µg/100 g body weight) or T 3 (1 µg/100 g body weight). ME RNA was determined by Northern blot analysis and data expressed as PIU, relative to a non-regulated cyclophilin RNA. Data points are means ..; n=5. potency of T 3 in anti-goitre assays in vivo (Stasilli et al. 1959) . However, T 2 has rapid and specific effects on oxidative metabolism in rat liver and in mononuclear blood cells (Horst et al. 1989 , Kvetny 1992 , Lanni et al. 1992 , Goglia et al. 1994 . T 3 regulates gene expression through TR interaction with TREs located in the promoter region of target genes. GH and hepatic ME gene expression are positively regulated by T 3 (Yaffe & Samuels 1984,  5 . In vitro competitive binding of T 2 and T 3 to in vitro translated TRs and GH 3 cell nuclear extract.  2. Calculated ED 50 s and T 3 and T 2 binding to in vitro translated TRs and GH 3 cell nuclear extracts
Selective thyromimetic effects of T 2 ·    and others 143
Journal of Molecular Endocrinology (1997) 19, 137-147 Dozin et al. 1986 ), while TR 2 and both subunit genes of TSH are negatively regulated (Hodin et al. 1990 . To confirm the thyromimetic activity of T 2 and to investigate its potential as a selective thyromimetic agent, we have examined the ability of T 2 to regulate these T 3 responsive genes in vivo and in vitro. The present studies not only confirm the thyromimetic activity of T 2 , but highlight the differential thyromimetic activity of the iodothyronine. Doseresponse curves of the stimulation of GH mRNA by T 2 and T 3 in GH 3 cells are parallel. However, T 3 is approximately 100 times more potent than T 2 in this process. In contrast to its relatively poor ability to stimulate the GH gene, T 2 is almost as effective as T 3 in downregulating TR 2 gene expression, concentrations of T 2 and T 3 resulting in halfmaximal reduction in TR 2 mRNA levels being equivalent. Not only does T 2 downregulate the TR 2 gene at doses which produce no effect on the GH gene, but it is nearly as effective as T 3 in mediating this process. The analogues sT 2 and T0 had no significant thyromimetic activity in our in vitro assays. These data indicate that T 2 has differential thyromimetic activity in vitro.
To complement these cell culture studies, we have investigated the thyromimetic properties of T 2 in vivo. At a dose of 100 µg/100 g body weight, T 2 produced a 2·0-fold decrease in plasma TSH. This reduction was significantly less than that produced by T 3 at a dose of 1 µg/100 g body weight.
In contrast, the induction of ME mRNA by 100 µg/100 g body weight T 2 was equivalent to that produced by 1 µg/100 g body weight T 3 (9·5-fold compared with 11·6-fold). Thus, at doses producing induction of ME equivalent to that obtained with 1 µg/100 g body weight T 3 , T 2 was relatively less effective at suppressing TSH. Though the different metabolism and bioavailability of the iodothyronines make accurate comparisons of relative thyromimetic activity in vivo difficult, these data clearly show that T 2 is more effective at inducing hepatic ME gene expression than in the suppression of plasma TSH. While these data could reflect a shift to the left in the dose-response curve for ME compared with that for TSH, with apparent equivalence thus resulting from supra-maximal doses of both iodothyronines, ME induction was not maximal at 1 µg/100 g body weight T 3 , making this unlikely (data not shown). These data indicate that, in keeping with the in vitro data, T 2 has differential thyromimetic activity in vivo.
We have performed further studies to define the molecular basis of this selective thyromimetic activity. To determine if the selective effects of T 2 are based on selective affinity of the iodothyronine for different TR isoforms, we performed a series of competitive binding studies using in vitro translated TRs. T 2 was approximately 40-500-fold less potent than T 3 in displacing [
125 I]-T 3 from in vitro translated TRs. We found ED 50 values for T 3 in the n range for all TRs, in keeping with published K d values (Schueler et al. 1990) ; ED 50 values for T 2 were consistently in the µ range. Similar results were obtained using GH 3 cell nuclear extracts as a source of TRs. Previous studies have shown that TR 1 has a low affinity for T 2 , with relative affinity constants similar to those found in the present study (Cheng et al. 1994) . There are no previous data on T 2 binding to TR 2. Though we have shown that TR 2 binds T 2 more avidly than do the other TRs, this apparent affinity remains substantially (40-fold) less than that for T 3 . These data indicate that the basis for the selective thyromimetic effects of T 2 is not simply selective binding to individual TR isoforms.
Receptor-mediated biological responses reflect a compound process. Ligand binding induces conformational changes in a receptor which, in turn, lead to an alteration in function. The affinity of a receptor for a ligand generally parallels the ability of that ligand to produce an alteration in conformation and function of the receptor following interaction with the ligand binding site. In the absence of T 3 , TRs can bind to inverted palindrome and directrepeat TREs as homodimers, monomers and heterodimers. The binding of T 3 to TRs results in dissociation of the homodimer-TRE complex. This ligand-induced dissociation of TR homodimers is thus a compound phenomenon, a reflection of both ligand binding and the resultant conformational change in the TR. The ability of T 2 to bind to and produce a conformational change in a TR was investigated by assessing the ability of the iodothyronine to dissociate TR 1 homodimers in an EMSA. T 2 is approximately 1000-fold less potent than T 3 in dissociating TR 1 homodimers from an F2-TRE. TR 1 and TR 2 do not readily form homodimers on the F2-TRE ; however, we have not tested the ability of T 2 to produce conformational changes in these isoforms. Nevertheless, these data indicate that, at least in the case of TR 1, the relative ability of T 2 to bind to and produce conformational changes in a TR is consistent with its relative binding affinity. The selective thyromimetic effects of T 2 are unlikely to reflect differences in the behaviour of T 2 in competitive binding and a compound functional assay in vitro.
Previous data have indicated that T 2 is capable of suppressing plasma TSH at doses that do not produce significant peripheral effects and, moreover, have shown T 2 to have selective central effects relative to T 3 (Horst et al. 1995) . Our data confirm the selective thyromimetic activity of T 2 in vivo and in vitro. However, we show that at in vivo doses of T 2 and T 3 resulting in equivalent induction of ME gene expression, T 2 is significantly less potent in suppressing plasma TSH. These data would suggest that, in vivo, although capable of suppressing TSH, T 2 does not have selective central thyromimetic activity, in fact being better at inducing hepatic ME gene expression than suppressing TSH (Horst et al. 1995) . The reasons for the discrepancy between the data from the present study and those from Horst et al. are not clear. We have looked directly at hepatic ME RNA expression as an index of peripheral thyromimetic activity, whereas Horst et al. monitored the effects of iodothyronines on body weight, organ size and food intake. It is possible that induction of hepatic ME mRNA is a more sensitive indicator of peripheral thyroid status than these more compound endpoints.
The mechanism(s) underlying the selective effects of T 2 remains unclear. We have excluded both selective TR interactions and discrepancies between standard in vitro assays of ligand binding and TR function as potential mechanisms. Previous studies have raised the possibility that T 2 may have extra-nuclear effects, independent of classical nuclear TRs (Horst et al. 1989 , Kvetny 1992 , Lanni et al. 1993 , Goglia et al. 1994 . Both GH and TSH mRNA levels can be regulated at a posttranscriptional level by T 3 (Jones et al. 1990 , Krane et al. 1991 . Similarly, ME synthesis in the liver is regulated at both transcriptional and posttranscriptional levels (Dozin et al. 1986) . Though the murine TR 2 promoter has recently been cloned, the regulation of TR 2 gene expression remains unclear (Wood et al. 1994) . There are data to suggest that TR 2 expression is also regulated at both transcriptional and post-transcriptional levels (Jones et al. 1993) . It is thus possible that the selective thyromimetic effects of T 2 , at least partially, reflect post-transcriptional events. Certainly the effects of T 2 on TR 2 mRNA occur at doses at which the TRs are minimally occcupied by the ligand, raising the possibility of a non-nuclear TR-mediated process. Alternatively, at a transcriptional level, the conformation of the T 2 -TR complex may accommodate selective interaction with co-activators involved in the expression of a limited number of specific TR-regulated genes. Further investigation of these phenomena will provide additional insight into the molecular mechanisms underlying the diversity and specificity of T 3 action.
